Suppr超能文献

[RET融合基因在非小细胞肺癌中的意义]

[Significances of RET fusion gene in non-small cell lung cancer].

作者信息

Liu Jingjing, Bi Minghong

机构信息

Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2013 Nov;16(11):615-20. doi: 10.3779/j.issn.1009-3419.2013.11.11.

Abstract

Lung cancer is the leading cause of cancer-related death worldwide, molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment. RET fusion gene with an identifiable clinical pathological features, is present in some subsets of lung cancer, and its treatment is effective by RET inhibitor, suggesting that RET fusion gene may be a new target for individualized treatment to the subgroup of NSCLC. This article reviews the structural characteristics of RET fusion gene and expression model in clinical samples, and treatment of NSCLC.

摘要

肺癌是全球癌症相关死亡的主要原因,分子靶向治疗已成为非小细胞肺癌(NSCLC)治疗的热门研究方向。RET融合基因具有可识别的临床病理特征,存在于部分肺癌亚组中,且其治疗可通过RET抑制剂实现有效,这表明RET融合基因可能是NSCLC亚组个体化治疗的新靶点。本文综述了RET融合基因的结构特征、在临床样本中的表达模式以及NSCLC的治疗情况。

相似文献

1
[Significances of RET fusion gene in non-small cell lung cancer].
Zhongguo Fei Ai Za Zhi. 2013 Nov;16(11):615-20. doi: 10.3779/j.issn.1009-3419.2013.11.11.
3
Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges.
Anticancer Drugs. 2023 Oct 1;34(9):979-984. doi: 10.1097/CAD.0000000000001483. Epub 2022 Dec 19.
4
Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Cancer Biol Ther. 2017 Nov 2;18(11):883-887. doi: 10.1080/15384047.2016.1235660. Epub 2016 Sep 16.
5
Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
Arch Pharm Res. 2015 Dec;38(12):2120-3. doi: 10.1007/s12272-015-0660-1. Epub 2015 Sep 16.
7
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
J Clin Oncol. 2012 Dec 10;30(35):4352-9. doi: 10.1200/JCO.2012.44.1477. Epub 2012 Nov 13.
8
How should "RET positive" NSCLC be treated?
Lung Cancer. 2017 Jun;108:250-251. doi: 10.1016/j.lungcan.2017.02.006. Epub 2017 Feb 6.
10
Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Mol Cancer Ther. 2014 Dec;13(12):2910-8. doi: 10.1158/1535-7163.MCT-14-0274. Epub 2014 Oct 27.

本文引用的文献

1
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.
2
RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer.
Cancer Med. 2012 Aug;1(1):68-75. doi: 10.1002/cam4.13. Epub 2012 Jul 12.
3
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
J Thorac Oncol. 2012 Dec;7(12):1872-1876. doi: 10.1097/JTO.0b013e3182721ed1.
4
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
J Clin Oncol. 2012 Dec 10;30(35):4352-9. doi: 10.1200/JCO.2012.44.1477. Epub 2012 Nov 13.
5
KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Oncol Rep. 2012 Oct;28(4):1187-92. doi: 10.3892/or.2012.1908. Epub 2012 Jul 13.
7
Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers.
Cell Res. 2012 May;22(5):928-31. doi: 10.1038/cr.2012.27. Epub 2012 Feb 21.
8
KIF5B-RET fusions in lung adenocarcinoma.
Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.
9
RET, ROS1 and ALK fusions in lung cancer.
Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验